Akcea Therapeutics Stock Price, News & Analysis (NASDAQ:AKCA)

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.02. The company earned $26.62 million during the quarter, compared to the consensus estimate of $25.78 million. Akcea Therapeutics had a negative net margin of 65.62% and a negative return on equity of 43.87%. Akcea Therapeutics's revenue was up 45.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.85) EPS. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Akcea Therapeutics.

4 equities research analysts have issued 12 month target prices for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $45.00. On average, they anticipate Akcea Therapeutics' stock price to reach $36.00 in the next year. This suggests a possible upside of 99.1% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

News stories about AKCA stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akcea Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Akcea Therapeutics.

Akcea Therapeutics saw a decline in short interest in September. As of September 30th, there was short interest totalling 5,160,000 shares, a decline of 14.3% from the August 30th total of 6,020,000 shares. Based on an average trading volume of 263,500 shares, the short-interest ratio is presently 19.6 days. Currently, 35.0% of the company's shares are short sold. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), FibroGen (FGEN) and Arrowhead Pharmaceuticals (ARWR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $18.08.

Akcea Therapeutics has a market capitalization of $1.68 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]